Alnylam blames the Inflation Reduction Act for a PhIII cut — would it have sold enough for negotiations?

Max Gelman

Senior Editor

Zachary Brennan

Senior Editor

Alnylam Pharmaceuticals, the pharma market’s leader in RNAi therapies, reported its third quarter earnings Thursday, updating shareholders on its pipeline progress and initial sales figures …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Alnylam blames the Inflation Reduction Act for a PhIII cut — would it have sold enough for negotiations?

Max Gelman

Senior Editor

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Al­ny­lam blames the In­fla­tion Re­duc­tion Act for a PhI­II cut — would it have sold enough for ne­go­ti­a­tions?

Senior Editor

Senior Editor

Sign up to read this article for free.

Alnylam blames the Inflation Reduction Act for a PhIII cut — would it have sold enough for negotiations?